Kariya and NeuraLight Partner to Enhance GLP-1 Therapies for Brain Impact
Kariya Pharmaceuticals and NeuraLight have formed a partnership to advance brain-focused GLP-1 therapeutic solutions. This collaboration will incorporate NeuraLight’s precision biomarker platform into Kariya’s Phase II clinical program for KP405, a dual GLP-1/GIP agonist aimed at treating Parkinson’s and Alzheimer’s diseases.
COPENHAGEN, Denmark & NEW YORK & TEL AVIV, Israel–(BUSINESS WIRE)–Kariya Pharmaceuticals, a pioneer in brain-penetrant GLP-1 therapies, and NeuraLight, the leader in developing precision brain function measures, today announced a partnership to advance brain-focused GLP-1 therapeutics. The partnership integrates NeuraLight’s precision biomarker platform into Kariya’s Phase II program for KP405, a first-in-class brain-penetrant dual GLP-1/GIP agonist in development for Parkinson’s and Alzheime